DaVita Inc. (DVA): Price and Financial Metrics


DaVita Inc. (DVA): $125.41

-0.53 (-0.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

DVA POWR Grades


  • DVA scores best on the Stability dimension, with a Stability rank ahead of 80.51% of US stocks.
  • DVA's strongest trending metric is Stability; it's been moving up over the last 206 days.
  • DVA's current lowest rank is in the Sentiment metric (where it is better than 37.7% of US stocks).

DVA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for DVA is 9.24 -- better than 96.66% of US stocks.
  • For DVA, its debt to operating expenses ratio is greater than that reported by 84.92% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 11.16 for Davita Inc; that's greater than it is for 93.17% of US stocks.
  • Stocks that are quantitatively similar to DVA, based on their financial statements, market capitalization, and price volatility, are FRTA, NCR, HBAN, CCB, and TPX.
  • Visit DVA's SEC page to see the company's official filings. To visit the company's web site, go to www.davita.com.

DVA Price Target

For more insight on analysts targets of DVA, see our DVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $123.71 Average Broker Recommendation 1.94 (Hold)

DVA Stock Price Chart Interactive Chart >

Price chart for DVA

DVA Price/Volume Stats

Current price $125.41 52-week high $129.59
Prev. close $125.94 52-week low $75.30
Day low $125.15 Volume 302,400
Day high $126.46 Avg. volume 751,324
50-day MA $112.56 Dividend yield N/A
200-day MA $103.23 Market Cap 13.32B

DaVita Inc. (DVA) Company Bio


DaVita Healthcare Partners delivers dialysis services to patients with chronic kidney failure and end stage renal disease. The company was founded in 1994 and is based in Denver, Colorado.

DVA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$125.41$151.84 24%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Davita Inc. To summarize, we found that Davita Inc ranked in the 60th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 24.5% on a DCF basis. The most interesting components of our discounted cash flow analysis for Davita Inc ended up being:

  • 54% of the company's capital comes from equity, which is greater than just 18.78% of stocks in our cash flow based forecasting set.
  • Davita Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 1.8% of tickers in our DCF set.
  • Relative to other stocks in its sector (Healthcare), Davita Inc has a reliance on debt greater than 86.92% of them.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%21%
1%23%
2%24%
3%25%
4%26%
5%28%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DVA, try JAZZ, PRAH, VCEL, BDX, and MCK.


DVA Latest News Stream


Event/Time News Detail
Loading, please wait...

DVA Latest Social Stream


Loading social stream, please wait...

View Full DVA Social Stream

Latest DVA News From Around the Web

Below are the latest news stories about Davita Inc that investors may wish to consider to help them evaluate DVA as an investment opportunity.

Extraordinary Nurses at DaVita Kidney Care Honored with DAISY Awards

DaVita Kidney Care today announced that 60 of its nephrology nurses were honored with The DAISY Award for Extraordinary Nurses® during National Nurses Week. The award is part of the DAISY Foundation's mission to recognize the extraordinary, compassionate care that nurses provide to patients and families every day.

Yahoo | May 13, 2021

Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

Investor confidence is high on the DaVita (DVA) stock, courtesy of its solid prospects.

Yahoo | May 12, 2021

5 of the Best Stocks to Buy Now for Striking Earnings Growth

Herbalife (HLF), DaVita (DVA), Apple (AAPL), Century Communities (CCS) & Repligen (RGEN) are the top stocks that flaunt attractive earnings growth at present.

Yahoo | May 7, 2021

DaVita's (DVA) CEO Javier Rodriguez on Q1 2021 Results - Earnings Call Transcript

DaVita, Inc. (DVA) Q1 2021 Earnings Conference Call April 29, 2021 5:00 PM ET Company Participants Jim Gustafson – Vice President, Investor Relations Javier Rodriguez – Chief Executive Officer Joel Ackerman – Chief Financial Officer Conference Call Participants Pito Chickering – Deutsche Bank Kevin Fischbeck – Bank of America Justin...

SA Transcripts on Seeking Alpha | April 30, 2021

DaVita (DVA) Q1 Earnings Beat Estimates, Revenues Miss Mark

DaVita's (DVA) net dialysis and related lab-patient service revenues rise in Q1.

Yahoo | April 30, 2021

Read More 'DVA' Stories Here

DVA Price Returns

1-mo 14.16%
3-mo 19.45%
6-mo 10.84%
1-year 58.25%
3-year 87.66%
5-year 62.72%
YTD 6.82%
2020 56.47%
2019 45.80%
2018 -28.78%
2017 12.54%
2016 -7.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8863 seconds.